¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"cardioselective beta-adrenoreceptor blocker"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® beta-blocker ÇÑ±Û º£Å¸Â÷´ÜÁ¦
¼³¸í   
  º£Å¸-¼ö¿ëü(1°ú 2¿¡ °ü°è¾øÀÌ)ÀÇ ±â´ÉÀ» ¾ïÁ¦½Ã۴ ¾à¹°·Î ÀÌ ¼ö¿ëü°¡ ¸Å°³ÇÏ¿© »ý±â´Â ½ÅüÀÇ º¯È­¸¦ ¾ïÁ¦ÇÑ´Ù. PropranololÀÌ ÁÁÀº ¿¹ÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cardioselective
    ½ÉÀå¼±Åüº-
  • axon blocker
    Ãà»èÂ÷´ÜÁ¦
  • adrenergic blocker
    ¾Æµå·¹³¯¸°Â÷´ÜÁ¦
  • blocker
    Â÷´Ü±â, Â÷´ÜÁ¦
  • calcium-channel blocker
    Ä®½·Åë·ÎÂ÷´ÜÁ¦
  • neuromuscular blocker
    ½Å°æ±Ù(À°)Â÷´ÜÁ¦
  • receptor blocker
    ¼ö¿ëüÂ÷´ÜÁ¦
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • blocker
    Â÷´Ü±â, Â÷´ÜÁ¦
  • receptor blocker
    ¼ö¿ëüÂ÷´ÜÁ¦
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adrenergic blocker
    ¾Æµå·¹³¯¸°Â÷´ÜÁ¦
  • axon blocker
    Ãà»èÂ÷´ÜÁ¦
  • blocker
    Â÷´Ü±â, Â÷´ÜÁ¦
  • neuromuscular blocker
    ½Å°æ±ÙÀ°Â÷´ÜÁ¦
  • receptor blocker
    ¼ö¿ëüÂ÷´ÜÁ¦
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cardioselective beta-adrenoreceptor blocker
    ½ÉÀå ¼±Åüº º£Å¸Â÷´ÜÁ¦(ãýíôàÔ÷Éàõ - ó´Ó¨ð¥)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • beta blocker
    º£Å¸ Â÷´ÜÁ¦( -ó´Ó¨ð¥)
  • beta blocker
    º£Å¸ Â÷´ÜÁ¦(ó´Ó¨ð¥)
  • beta receptor blocker
    º£Å¸¼ö¿ëü Â÷´ÜÁ¦( -áôé»ô÷ ó´Ó¨ð¥)
  • blocker
    Â÷´Ü(ó´Ó¨).
  • blocker
    Â÷´ÜÁ¦, Æó»ö¹°, ºÀ¼âÁ¦<¾à¹°>.
  • blocker/blocking agent
    Â÷´ÜÁ¦
  • blocking antibody =blocker
    Â÷´ÜÇ×ü(¡­ù÷ô÷).
  • bronchial blocker
    ±â°üÁö Â÷´Ü¹°(Æó¼â¹°)
  • calcium channel antagonist,blocker
    Ä®½·Åë·Î ±æÇ×Á¦( -÷×ÖØ ÑÏù÷ð¥),Â÷´ÜÁ¦(ó´Ó¨ð¥).
  • calcium channel blocker ; calcium channel blocking drug
    Ä®½·Åë·ÎºÀ¼â¾à ¹°<Á¦>, Ä®½·Åë·Î Â÷´Ü¾à¹°<Á¦>.
  • calcium channel blocker ; calcium channel blocking drug
    Ä®½·Åë·ÎºÀ¼â¾à¹°<Á¦>, Ä®½·Åë·ÎÂ÷´Ü¾à¹°<Á¦>.
  • depolarizing blocker
    Â÷´ÜÁ¦(ó´Ó¨ð¥).
  • ion channel blocker
    ÀÌ¿ÂÅë·ÎÂ÷´ÜÁ¦
  • neuromuscular blocker
    ½Å°æ±ÙÂ÷´Ü<ºÀ¼â>Á¦.
  • neuromuscular blocker
    ½Å°æ±ÙÂ÷´ÜÁ¦.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • alpha blocker
    ¾ËÆÄÂ÷´ÜÁ¦(ó´Ó¨ð¥)
  • beta adrenergic blocker
    º£Å¸ ¾Æµå·¹³¯¸°ÀÛµ¿(íÂÔÑ) Â÷´ÜÁ¦(ó´Ó¨ð¥)
  • beta blocker
    º£Å¸ Â÷´ÜÁ¦(ó´Ó¨ð¥)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • beta blocker
    º£Å¸Â÷´ÜÁ¦
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
Ca2+-blocker calcium channel blocker
BB bad breath; bed bath; beta blockade, beta blocker; BioBreeding [rat]; blanket bath; blood bank; bloo...
BHAT Beta Blocker Heart Attack Trial
CB Bachelor of Surgery [Lat. Chirurgiae Baccalaureus]; calcium blocker; carbenicillin; carotid body; ch...
CCB calcium channel blocker
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ARB angiotensin receptor blocker
ARB Angiotensin II receptor blocker
BHAT Beta-Blocker Heart Attack Trial
CCB Calcium channel blocker
CEB Calcium entry blocker
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cardioselective
    ½ÉÀå ¼±ÅÃÀû
    ´Ù¸¥ Á¶Á÷º¸´Ù ½ÉÀå Á¶Á÷¿¡ ´õ Å« Ȱµ¿¼ºÀ» °¡Áø.
  • 2 blocker
    2 Â÷´ÜÁ¦
  • alpha 1-adrenergic blocker
    ¾ËÆÄ 1-¾Æµå·¹³¯¸°¼º Â÷´Ü
  • beta receptor blocker
    º£Å¸ ¼ö¿ëü Â÷´ÜÁ¦
  • calcium channel blocker
    Ä®½· Åë·Î ºÀ¼â ¾à¹°, Ä®½· Åë·Î Â÷´Ü ¾à¹°, Ä®½· ä³Î Â÷´ÜÁ¦
    µ¿ÀǾî=calcium channel blocking drug. 1. Ä®½·ÀÌ Åë°úÇÏ ´Â µµ°üÀ» ¸·´Â ¾à¹°. 2. Ç× Çù½ÉÁõ Á¦Á¦, Ç×°íÇ÷¾Ð Á¦Á¦, Ç× ºÎÁ¤¸Æ Á¦Á¦·Î »ç¿ëµÇ´Â ¾à¹°·Î½á, µ¿¸ÆÀÇ ÆòȰ±Ù¿¡¼­ Ä®½·ÀÇ À¯ÀÔÀ» Â÷´ÜÇÔÀ¸·Î½á ¸»ÃÊ ¼Òµ¿¸ÆÀ» ÀÌ¿ÏÇØ¼­ ½É±ÙÀÇ »ê¼Ò ¿ä±¸·®À» ÀúÇϽÃŰ´Â ±â´ÉÀ» ÇÑ´Ù. ´ëÇ¥ÀûÀÎ ¾à¹°·Î´Â, vera
  • calcium-channel blocker
    Ä®½· Â÷´ÜÁ¦, Ä®½· Åë·Î Â÷´ÜÁ¦
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
cardioselective Having greater activity on heart tissue than on other tissue.
(18 Nov 1997)
alpha-blocker An agent that competitively blocks alpha-adrenergic receptors; used in the treatment of hypertension.
Synonym: alpha-blocker.
(05 Mar 2000)
beta-blocker <pharmacology> A large group of medications that act to block specific receptors in the nervous system. A drug that induces adrenergic blockade at either á1 or á2 adrenergic receptors or at both.
The effect of beta-blockade results in slowing of the heart rate, reduction in blood pressure and reduced anxiety. Beta-blockers are used in the treatment of angina, heart arrhythmias, high blood pressure, mitral valve prolapse and other conditions.
(06 Oct 1997)
blocker 1. An instrument used to obstruct a passage.
See: blocking agent.
(05 Mar 2000)
calcium channel-blocker <pharmacology> A class of drugs that act by selective inhibition of calcium ion influx through or across cell membranes or on the release and binding of calcium in intracellular pools.
Calcium channel blockers are used primarily in the treatment of certain heart conditions and stroke. As they are inducers of vascular and other smooth muscle relaxation, they are also used in the treatment of hypertension and cerebrovascular spasms, as myocardial protective agents, and in the relaxation of uterine spasms.
Synonym: calcium antagonist, calcium channel-blocker, slow channel-blocking agent.
(12 May 2002)
medication, beta-blocker Drugs that antagonise the action of adrenaline (a beta adrenergic substance) and relieve stress to the heart muscle. Beta-blockers are often used to slow the heart rate or lower the blood pressure.
(12 Dec 1998)
H2 blocker <pharmacology> A class of anti-ulcer medication which work through the inhibition of basal and nocturnal gastric acid secretion by competitive inhibition of the action of histamine at histamine H2 receptor sites on the parietal cells.
Drugs of this type block gastric acid secretion and are therefore clinically useful in treating duodenal ulcers.
Examples include cimetidine (Tagamet), famotidine (Pepcid), nizatidine (Axid) and ranitidine (Zantac).
(27 Sep 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á